Cancer is a multistage multimechanism process involving gene and/or chromosomal mutations (genotoxic events), altered gene expression at the transcriptional, translational, and posttranslational levels (epigenetic events), and altered cell survival (proliferation and apoptosis or necrosis), resulting in an imbalance of the organism's homeostasis. Maintenance of the organism's homeostasis depends on the intricate coordination of genetic and metabolic events between cells via extracellular and intercellular communication mechanisms. The release of a quiescent cell, whether normal or premalignant, from the suppressing effects of communicating neighbors requires the downregulation of intercellular communication via gap junctions, thereby allowing factors that control intracellular events to exceed a critical mass necessary for the cell to either proliferate or undergo apoptosis. Therefore, determining the role an environmental pollutant must play in the multistage carcinogenic process includes mechanisms of epigenetic toxicity such as the effects of a compound on gap junctional intercellular communication (GJIC). A classic example of a class of compounds in which determination of carcinogenicity focused on genotoxic events and ignored epigenetic events is polycyclic aromatic hydrocarbons (PAHs). The study of structure-activity relationships of PAHs has focused exclusively on the genotoxic and tumorinitiating properties of the compound. We report on the structure-activity relationships of two-to four-ringed PAHs on GJIC in a rat liver epithelial cell line. PAHs containing a bay or baylike region were more potent inhibitors of GJIC than the linear PAHs that do not contain these regions. These are some of the first studies to determine the epigenetic toxicity of PAHs at the epigenetic level.
Experimental animal studies, for a wide variety of reasons, have additional limitations and they also cannot provide underlying mechanisms by which a given chemical might or might not lead to human diseases. Molecular, biologic, and cellular studies, which can provide potential mechanistic insights as to how chemicals might be toxic, also suffer from limitations of all sorts (1) .
To put chemicals in animals and check to see if disease can be induced, to check humans known to be exposed to a given chemical for the appearance of disease, and to measure DNA lesions, mutations, and cell death in vitro will not be sufficient to link a chemical as causing a disease via this or that mechanism. The reason is fundamental; all observations, epidemiologic or experimental bioassays, or in vitro assays are interpreted within accepted paradigms. The design and interpretation of the experiments and results presume some understanding of the disease processes and the techniques used to determine mechanisms. Although the field of toxicology existed long before Carson's Silent Spring (2) and societies have been concerned about exposures to certain chemicals since the dawn of time, heightened concern in recent decades has caused a rush to test chemicals already in use and known or suspected of contributing to human disease and to test chemicals in development. Understandably, testing protocols, guidelines for use and exposure, and decision-making interpretations for evaluation of the results must involve state-of-the-art information in our understanding of the causes of disease and the meaning ofvarious test results.
Although this analysis must be limited to one disease, namely cancer, the implications probably hold true for most, if not all, human diseases. A major problem in the task of identifying the risk of cancer induction after exposure to a given toxicant is understanding how cancer is produced in a human being and how a toxicant might contribute to that process. One (14) ]. Cancer as a disease of differentiation or as a stem cell disease (15) suggests that during the carcinogenic process these cells lost their ability for homeostatic control. This implies a breakdown in one of the three communicating mechanisms. Experimental evidence seems consistent with the hypothesis that cancer is a breakdown in cell-cell communication (16) . Most, if not all, cancer cells have defective homologous and/or heterologous GJIC (17) . Chemical tumor promoters inhibit GJIC, whereas chemical antipromoters enhance GJIC (18) . Oncogenes downregulate GJIC, whereas tumor suppressor genes upregulate GJIC (16) . Antisense gap junction genes in normal cells render them cancerlike (19, 20) , whereas sense gap junction genes transfected into cancer cells restore their normal growth regulation (16) .
Carcinogenesis as a Multistage Multimechanism Process Involves Both Mutagenic and Epigenetic Events
The observations that carcinogenesis consists of distinct operational phases during the evolution of a normal growthcontrolled cell to an invasive and metastatic neoplastic growth disregulated and nonterminally differentiated cell led to the concepts of initiation, promotion, and progression (21) . The concepts were derived in vivo after it was observed that subcarcinogenic doses of a carcinogen induced an irreversible event in a cell of the mouse skin (initiation), which could be manifested as a visible papilloma, after repeated chronic exposure to a noncarcinogenic compound such as phorbol ester (promotion) (22, 23) .
Further irreversible changes occurring in these initiated cells that have been clonally amplified by the promotion process then leads to a malignant tumor cell (24) . Although the underlying mechanisms for these distinct phases of carcinogenesis are not yet known, it has been hypothesized that because initiation is an irreversible event, mutagenesis could be the mechanism by which a normal stem cell could be irreversibly altered to prevent terminal differentiation (21 (26) in which 301 chemicals were assessed for mutagenicity and carcinogenicity. Although this study indicated that structurally alerting/mutagenic agents had a high probability of being carcinogenic (84% mutagens were carcinogens), this correlative advantage was offset by an unacceptable high incidence of false-positive predictions (66% noncarcinogens were mutagens) (26) . Also, many nonmutagenic/nonalerting chemicals were carcinogenic (26) . This was especially true for male rat kidney carcinogens, rodent leukemogens and thyroid carcinogens, and mouse liver carcinogens (26) .
This unfortunately led to the negative term nongenotoxic carcinogens. The term does not indicate the underlying mechanisms of carcinogenicity but refers only to what the compound cannot do, i.e., the compound cannot cause a permanent genetic mutation. To the contrary, the term epigenetic toxicity implies a mechanism of reversibly altering the genetic phenotype of a cell through biochemical pathways that ultimately turn genes on and off via intracellular pathways, a process under the homeostatic control of neighboring cells via intercellular communication through gap junctions (15, 16) . Because intracellular pathways often converge onto intercellular events (15) , the development of in vitro assay systems that measure GJIC has been successfully used to detect many epigenetic carcinogens (27, 28 (29) . The potential human carcinogenicity of PAHs is based on many years of observation in animal and in vitro bioassays, epidemiology, and occupational medicine (29) . Actually, the earliest association of an environmental agent linked to human cancer was made by Pott (30) , who reported that prolonged contact of coal soot with skin resulted in increased scrotal cancer in chimney sweeps. The (33) . The carcinogenic studies of structure-activity relationships of PAHs reported in the literature focused almost exclusively on either the complete carcinogenicity or tumor-initiating activity of PAHs (33, 34) . However, reports in the literature of the tumor-promoting properties of PAHs are sparse. This lack of data on structure-activity relationships of PAHs pertaining to tumor promotion is unfortunate considering that human risk from a carcinogen does not rest solely on the initiating properties of a chemical, particularly because many suspected carcinogens are not genotoxic (35) and some genotoxic agents are noncarcinogenic and lack initiating activity (12) .
For example, fluoranthene intraperitoneally injected into mouse neonates showed increased lung and liver tumors in a dose-dependent manner (35, 36) , but did not show any evidence of tumor-initiating activity in experimental animals (29) or in in vivo genotoxicity, as assessed using the mouse bone marrow micronucleus and rat liver unscheduled DNA synthesis assays (37) . The tumor-promoting activity of fluoranthene has not been determined; however, fluoranthene downregulates GJIC in a rat liver epithelial cell line (38) , which suggests that fluoranthene may be a tumor promoter because of its epigenetic properties.
Understanding the molecular basis of the carcinogenicity of PAHs must include a study of nongenotoxic series of epigenetic events such as those that affect GJIC, for reasons outlined in our discussion of GJIC biology.
Some structure-activity relationships of PAHs and GJIC have been reported by Upham et al. (39) , who showed that monomethyl isomers of anthracene that possessed a baylike region ( Figure 2) were more inhibitory than the parent compound or the monomethyl isomer containing no baylike region.
A PAH containing a bay region, such as phenanthrene (Figure 2) , was also more inhibitory than anthracene (38) . To increased inhibitory effect of PAHs containing bay or baylike regions was even more pronounced with the three-ring PAHs ( (Tables 2 and 3 ). However, fluorene, which contains no bay or baylike region, did inhibit GJIC but at a higher dose than fluoranthene (Table 3) . Apparently the pentyl ring, in addition to bay regions, also increased the toxic effect of a PAH on GJIC.
Inhibition of GJIC by all of the PAHs tested was also a reversible process.
Complete recovery occurred within 2 hr and 50% recovery occurred within 1 hr after replacing the PAH-containing medium with that of fresh growth medium. These results are consistent with the reversible nature of tumor promotion in vivo (16) . Inhibition occurred in a short time period (< 5 min) for all of the PAHs ( Table 4 ), indicating that the gap junction proteins are being modified at the posttranslational level. The more water-soluble GJIC-inhibiting PAHs, which have lower log octanol/water partition coefficients (log Kow), downregulated GJIC in a shorter time period than the less water-soluble PAHs (Table 4) . This relationship of log Kow versus inhibition of a PAH was linear with an r2 of 0.69 and could indicate that the cell receptor for the PAHs is more accessible in an aqueous environment.
The tumor-promoting activity of the PAHs used in our study has not been determined. However, the cocarcinogenic effect of benz[a]anthracene, phenanthrene, fluoranthene, and 3-methylcholanthrene, all of which possess bay or baylike regions, (33) in which phenanthrene and fluoranthene lack tumor-initiating activity (37, 41, 45, 46) . The concept of bay or baylike regions possessing tumor-promoting activity certainly warrants further investigation. The methylated PAHs are more potent carcinogens than their unmethylated parent structure (45) (46) (47) (48) (49) (50) (51) (52) (53) (Tables 1-4) . These results suggest a similar mechanism of action. Therefore, randomly selecting one or two of these chemicals rather than testing all of them could minimize in vivo experiments. Minimizing in vivo experiments is a particularly important motivation factor in reducing the expense and use of live animals when assessing the risk of chemicals before and after environmental remediation. To test every subtle change in existing environmental remediation strategies using in vivo assays would certainly be prohibitively costly and inhumane, and to limit in vitro assays to the measurement of genotoxicity would exclude the accurate assessment of risks to human health considering that many chemicals, including many carcinogens, are epigenetically toxic (16, 17) . Furthermore, monitoring the levels of known toxicants using analytical chemical techniques is not an acceptable alternative to eliminating in vivo experiments because simply removing the parent compound does not always ensure a safe environment: Toxic by-products could result from the chemical or biologic transformation of the parent compound (64) . An example of such a situation was demonstrated by Upham et al. (38, 64) , in which selected PAHs were oxidatively removed using ozone but the resulting mixture became more epigenetically toxic than the parent compound.
In conclusion, the evaluation of epigenetic toxicity using in vitro assays should provide invaluable information in assessing the toxic risk of pollutants on human health before and after environmental remediation.
